![]() |
|
| November 10-14, 2009 Marriott Marquis, New York City | |
The Chemotherapy Foundation Symposium XXVII
![]()
| TUESDAY, NOVEMBER 10 | ||
| PEDIATRIC ONCOLOGY | ||
| Chair: Conrad Fernandez, MD | ||
| 1:45 | HIGHER RISK FAVORABLE HISTOLOGY IN WILMS TUMOR | |
| David Dix, MD | ||
| 2:00 | LOW-RISK RHABDOMYOSARCOMA |
|
| David Walterhouse, MD | ||
| 2:15 | OPTIMIZING TREATMENT FOR RESECTABLE OSTEOSARCOMA | |
| Neyssa Marina, MD | ||
| 2:30 | NEW INTERNATIONAL PROTOCOL FOR PATIENTS WITH INTRA-OCULAR RETINOBLASTOMA |
|
| Ira Dunkel, MD | ||
| 2:45 | NEW APPROACHES TO THE TREATMENT OF CHILDHOOD NASOPHARYNGEAL CARCINOMA | |
| Carlos Rodriguez-Galindo | ||
| 3:00 | Coffee Time | |
| 3:15 | HEMATOPOIETIC CELL TRANSPLANTATION FOR NEUROBLASTOMA |
|
| Sandeep Soni, MD | ||
| 3:30 | KIR INCOMPATIBILITY IN UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION FOR PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA |
|
| Robert Iannone, MD | ||
| 3:45 | INTRAVENOUS ASPARAGINASE IN PEDIATRIC HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA |
|
| Anne Angiolillo. MD | ||
| 4:00 | UPDATE ON THE MANAGEMENT OF RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA |
|
| Susan Rheingold, MD | ||
| 4:15 | LATE EFFECTS OF PEDIATRIC CANCER TREATMENT | |
| Peter Manley, MD | ||
| 4:30 | NEUROCOGNITIVE FUNCTION IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA |
|
| Naomi Winick, MD | ||
| 4:45 | FUNGAL INFECTIONS IN PEDIATRIC PATIENTS | |
| Theoklis Zaoutis, MD | ||
| 5:00 | THROMBOSIS IN CANCER PATIENTS | |
| Anne Hurlet, MD | ||
| 7 -9 pm | DINNER AND SPECIAL PRESENTATION | |
| MANAGEMENT OF THE ADOLESCENT OR YOUNG ADULT WITH CANCER |
||
| Robet J. Arceci, MD, PhD | ||
| PROGRESS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA | ||
| Archie Bleyer, MD | ||
| WEDNESDAY, NOVEMBER 11 | ||
| 7:00am | BREAKFAST WITH THE PROFESSORS | |
| LENALIDOMIDE: AN EMERGING TREATMENT OPTION IN CLL | ||
| Alessandra Ferrajoli, MD | ||
| HIGH DOSE LENALIDOMIDE IN AML OF THE ELDERLY | ||
| Ravi Vij, MD | ||
| 8:00 | WELCOME | |
| Steven Burakoff, MD, Janice L. Gabrilove, MD, Edward P. Ambinder, MD | ||
| MORNING SESSION | ||
| HEMATOLOGIC MALIGNANCIES | ||
| Moderators: Janet Cuttner, MD, Janice L. Gabrilove, MD, Kanti Rai, MD | ||
| MYELOPROLIFERATIVE/MYELODYSPLASTIC DISORDERS | ||
| New Approaches and New Agents | ||
| 8:10 | NEW THERAPEUTIC OPTIONS IN MYELOPROLIFERATIVE NEOPLASMS | |
| Ronald Hoffman, MD | ||
| 8:40 | FRONTLINE AND SALVAGE STRATEGIES IN MYELODYSPLATIC SYNDROME | |
| Hagop Kantarjian, MD | ||
| 8:55 | JAK2 IN HEMATOPOIESIS AND STATUS OF ANTI-JAK2 TRIALS | |
| Richard Silver, MD | ||
| 9:10 | TREATMENT OF HIGH RISK AML | |
| Janice Gabrilove, MD | ||
| 9:25 | LOMUSTINE (CCNU) WITH IDARUBICIN AND CYTARABINE IN ELDERLY PATIENTS WITH AML | |
| Arnaud Pigneux, MD | ||
| 9:40 | REVISITING MAINTENANCE THERAPY IN AML | |
| Gail Roboz, MD | ||
| 9:55 | BENDAMUSTINE IN CLL | |
| Bruce Cheson, MD | ||
| 10:10 | Coffee Time | |
| 10:40 | MANAGEMENT OF RESISTANT REFRACTORY CML |
|
| Jorge Cortes, MD | ||
| 10:55 | HDAC INHIBITORS: ENHANCING THE EFFICACY OF ANTI-MYELOMA DRUGS |
|
| James Berenson, MD | ||
| 11:10 | CPX 351 IN ACUTE LEUKEMIA | |
| Eric Feldman, MD | ||
| 11:25 | MAYO RISK STRATIFICATION FOR MULTIPLE MYELOMA | |
| Preshant Kapoor, MD | ||
| 11:40 | FOSTAMATINIB DISODIUM (R788) IN ITP AND B CELL LYMPHOMAS | |
| Jonathan Friedberg, MD | ||
| 11:55 | UPDATE ON LBH 589 HISTONE DEACETYLASE ACTIVITY IN LYMPHOMA |
|
| 12:05 | Lunch & Presentations | |
| FIVE YEARS WITH PROTEASOME INHIBITORS THE BACKBONE OF MEYLOMA THERAPY |
||
| Kenneth Anderson, MD | ||
| Sergio Giralt MD | ||
| AFTERNOON SESSION | ||
| GI CANCERS | ||
| Moderators: Jordan Berlin, MD, Howard S. Hochster, MD, | ||
| 1:50 | PANITUMUMAB AND COMBINATION CHEMOTHERAPY IN FIRST AND SECOND LINE THERAPY OF CRC CANCER | |
| Emily Chan, MD | ||
| 2:05 | CEDIRANIB AN ACTIVE VEGF INHIBITOR IN COLORECTAL CANCER | |
| Paolo Hoff, MD | ||
| 2:20 | COLORECTAL CANCER SCREENING: WHERE ARE WE IN 2009? | |
| Steven Itzkowitz, MD | ||
| 2:35 | TOGA, TOGA, TOGA: THE STORY OF TRASTUZUMAB IN HER2-POSITIVE GASTRIC CANCER | |
| Charles D. Blanke, MD | ||
| 2:50 | C-MET INHIBITOR THERAPY IN GASTRIC CANCER | |
| Manish Shah, MD | ||
| 3:00 | Coffee Time | |
| 3:30 | GEMCITABINE+ NAB-PACLITAXEL IN SPARC IN PANCREATIC CANCER |
|
| Ramesh Ramanathan, MD | ||
| 3:40 | OVERVIEW OF APPENDICEAL CARCINOMAS | |
| Heine Hansen, MD | ||
| 3:55 | SURVIVAL IN ADVANCED BILIARY TRACT CANCER | |
| Juan Valle, MD | ||
| 4:05 | HEDGEHOG PATHWAY IN GI CANCER | |
| Deirdre Cohen, MD | ||
| 4:20 | mTOR INHIBITION IN GI CANCER | |
| Johanna Bendell, MD | ||
| 4:35 | VEGF INHIBITION IN NEUROENDOCRINE TUMORS OF GI TRACT | |
| Jordan Berlin, MD | ||
| 4:50 | Discussion | |
| 6:00 | Reception | |
| 7 - 9 pm | DINNER AND PRESENTATIONS | |
| UPDATES IN MANTLE CELL LYMPHOMA | ||
| John P. Leonard, MD | ||
| THURSDAY, NOVEMBER 12 | ||
| 7:00am | BREAKFAST WITH THE PROFESSORS | |
| NEW DATA ON OPTIMIZING TAXANE USE IN METASTATIC BREAST CANCER | ||
| Andrew Seidman, M.D. | ||
| OVERVIEW OF PARP ACTIVITY IN SOLID TUMORS Merrill Egorin, MD |
||
| Morning SESSION | ||
| Moderators: Franco M. Muggia, MD, Carmel Cohen, MD | ||
| 8:00 | RECURRENT OVARIAN CANCER: NEW DEVELOPMENTS | |
| Franco Muggia, MD | ||
| 8:15 | CURRENT CLINICAL TRIALS IN OVARIAN CANCER | |
| Thomas Herzog, MD | ||
| 8:30 | OVERVIEW OF NATIONAL AND INTERNATIONAL CLINICAL TRIALS | |
| William McGuire, MD | ||
| 8:45 | MOVING BEYOND STANDARD CARE: NOVEL TREATMENTS IN GYNECOLOGIC MALIGNANCIES |
|
| Don Dizon, MD | ||
| 9:00 | A TARGETED THERAPY FOR RELAPSED OVARIAN CANCER | |
| Ursula Matulonis, M.D. | ||
| 9:15 | BRCA FUNCTION: A KEY FACTOR IN DETERMINING OUTCOME IN OVARIAN CANCER | |
| Tamar Safra, M | ||
| 9:30 | THE ROLE OF PARP INHIBITORS IN OVARIAN CANCER TREATMENT | |
| Hilary Calvert, MD | ||
| 9:45 | Discussion | |
| 10:00 | Coffee Time | |
| MELANOMA | ||
| 10:30 | BIOMARKER LINKS ENHANCED RESPONSE TO OBLIMERSEN SODIUM | |
| Sanjiv Agarwala, MD | ||
| 10:45 | PROSPECTIVE ANALYSIS OF BRAIN METASTASES IN MELANOMA | |
| Iman Osman | ||
| 10:55 | WEB-BASED PROGNOSTIC INDICATOR FOR MALIGNANT MELANOMA | |
| Charles M. Balch, MD | ||
| 11:10 | Discussion | |
| HEAD & NECK CANCER | ||
| 11:25 | ACTIVITY OF C225 IN HEAD AND NECK CANCER | |
| Walter Curran, MD | ||
| SARCOMA | ||
| 11:40 | TARGETING TUMOR HYPOXIA WITH TH-302: MONOTHERAPY & CHEMOTHERAPY: SARCOMAS AND OTHER SOLID TUMORS |
|
| Sant P Chawla MD | ||
| 11:50 | Discussion | |
| 12 Noon | Lunch & Presentations | |
| GENE EXPRESSION PROFILE | ||
| Role in Node Negative and Node Positive BC | ||
| Harold Burstein, MD, PhD | ||
| Predicting Colon Cancer Recurrence Risk | ||
| Norman Wolmark, MD | ||
| 1:30 | EZRA M. GREENSPAN MEMORIAL LECTURE | |
| SUCCESSES IN PHASE I TRIALS USING GENOMIC AND CLINICAL CONTEXTS OF VULNERABILITY | ||
| Daniel Von Hoff, MD | ||
| AFTERNOON SESSION | ||
| BREAST CANCER | ||
| Moderators: Seymour Cohen, MD, George Raptis, MD | ||
| 1:50 | IXABEPILONE: ACTIVE AGAINST TRIPLE-NEGATIVE BREAST CANCER |
|
| Howard Burris, MD | ||
| 2:05 | PARP1 INHIBITION IN TRIPLE NEGATIVE BREAST CANCER | |
| Cynthia Osborne, MD | ||
| 2:20 | PI3K INHIBITORS: OVERVIEW OF A NOVEL ANTICANCER TARGET |
|
| Howard Burris, MD | ||
| 2:35 | MECHANISMS OF RESISTANCE TO HER2 KINASE INHIBITORS | |
| Neil Spector, MD | ||
| 2:50 | HER3 MEASUREMENT IN BC AND CLINICAL OUTCOMES | |
| Allan Lipton, MD | ||
| 3:05 | Coffee Time | |
| 3:35 | IMC-A12 ALONE OR COMBINED WITH ANTIESTROGENS FOR PROGRESSION ON ANTIESTROGEN THERAPY | |
| William Gradishar, MD | ||
| 3:50 | NOVEL ANTI-HER2 THERAPIES: AN UPDATE ON TRASTUZUMAB-DM1 | |
| Harold Burstein, MD | ||
| 4:05 | NOVEL TARGETED THERAPIES IN HER2 NEGATIVE METASTATIC BREAST CANCER | |
| Susan Dent, MD | ||
| 4:30 | Discussion | |
| THYROID | ||
| 4:45 | NEW ADVANCES IN THE TREATMENT OF ADVANCED THYROID CANCER | |
| Marcia Brose, MD | ||
| 4:55 | Discussion | |
| 7 - 9pm | Dinner and Presentation | |
| UPDATE ON THE AVANT STUDY | ||
| Paulo Hoff, MD | ||
| FRIDAY, NOVEMBER 13 | ||
| Breakfast with the Professors | ||
| Chair: Steven Burakoff, MD | ||
| 7:00 | IMMUNOTHERAPY: CONTINUUM OF PROGRESS | |
| Steven Burakoff, MD | ||
| 7:45 | Discussion | |
| MORNING SESSION | ||
| URO-ONCOLOGY | ||
| Moderators: Anna C Ferrari, MD, William K. Oh Prostate | ||
| Prostate | ||
| 8:00 | IMATINIB AND DOCETAXEL PHASE II STUDY | |
| Gurkamal Chatta, MD | ||
| 8:15 | DOCETAXEL AND LENALIDOMIDE TRIAL IN PROSTATE CA | |
| Daniel Petrylak, MD | ||
| 8:30 | VACCINE THERAPY FOR PROSTATE CANCER | |
| Anna Ferrari, MD | ||
| 8:45 | AGENTS AND PHASE II PROSTATE CANCER CLINICAL TRIALS IN DEVELOPMENT | |
| Celestia Higano, MD | ||
| 9:00 | NEOADJUVANT DOCETAXEL & BEVACIZUMAB IN HR LOCALIZED PROSTATE CANCER: WHAT ARE BEST ENDPOINTS OF EFFICACY? |
|
| William K. Oh, M.D. | ||
| Renal | ||
| 9:15 | DOXORUBICIN AND GEMCITABINE IN METASTATIC RENAL CELL CARCINOMA WITH SARCOMATOID FEATURES | |
| Naomi Haas, MD | ||
| 9:30 | PERIFOSINE, A NOVEL AKT INHIBITOR: ACTIVITY IN METASTATIC RENAL CANCER | |
| Thomas Hutson, DO, PharmD | ||
| 9:45 | Discussion | |
| 10:00 | Coffee Time | |
| LUNG CANCER | ||
Moderators Chandra Belani, M.D, Roman Perez-Soler, MD |
||
| 10:15 | ABT-888: AN ACTIVE PARP1 INHIBITOR | |
| Suresh Ramalingam, MD | ||
| 10:25 | GDC-0449 | |
| Patricia LoRusso, MD | ||
| 10:35 | VORINOSTAT IN COMBINATION WITH CHEMOTHERAPY FOR NSCLC | |
| Chandra Belani, MD | ||
| 10:45 | SALIRASIB IN ADVANCED KRAS MUTANT NON-SMALL CELL LUNG CANCER | |
| Gregory J. Riely, MD | ||
| NSCLC: Changing Treatment Paradigms | ||
| 11:00 | EGFR RESISTANCE AND BIOMARKERS | |
| Roman Perez-Soler, MD | ||
| 11:15 | PERSONALIZED CHEMOTHERAPY FOR NSCLC | |
| George Simon, MD | ||
| 11:30 | SURGICAL UPDATE ON NON-SMALL CELL LUNG CANCER & MALIGNANT PLEURAL MESOTHELIOMA | |
| Jessica Donington, MD | ||
| 11:45 | Discussion | |
| 12 Noon | LUNCH AND SPECIAL PRESENTATION | |
| MAINTENANCE THERAPY IN ADVANCED NSCLC: STATE OF THE ART OR STATE OF CONFUSION? |
||
| Chandra Belani, MD, Cory Langer, MD | ||
| KRAS MUTATIONS AND SELECTION OF TARGETED AGENTS IN NSCLC | ||
| George Blumenschein, MD | ||
| AFTERNOON SESSION | ||
| 1:15 | JUDAH FOLKMAN MEMORIAL LECTURE AN ODE TO A PIONEER | |
| Kathy D. Miller, MD | ||
| DIVERSE THERAPEUTICS | ||
| Moderators: Sylvia Adams, MD, Edward Ambinder, MD | ||
| 1:35 | UNKNOWN PRIMARY TUMOR: DO NEW DIAGNOSTIC METHODS INFLUENCE TREATMENT? | |
| 1:45 | Anne Kristine Moelller, MD | |
| 1:55 | CARFILZOMIB ACTIVITY IN SOLID TUMORS | |
| Jeffrey Infante, MD | ||
| 2:05 | FUNCTIONAL CT EVALUATION OF EVEROLIMUS AND BEVACIZUMAB IN NEUROENDOCRINE TUMORS | |
| James Yao, MD | ||
| 2:15 | BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMA | |
| Alexis Demopoulos, MD | ||
| 2:40 | IMMUNOGENICITY OF MONTANIDE ISA 51 ADJUVANT VERSUS CYTOKINE-MATURED DENDRITIC CELLS IN MELANOMA VACCINES | |
| Sylvia Adams, MD | ||
| 2:40 | CLINICAL TRIALS WITH THE NOVEL VDA PLINABULIN (NPI-2358) | |
| Monica Mita, MD | ||
| 2:50 | CTEP CLINICAL TRIALS | |
| John Wright, MD | ||
| 3:05 | EVOLVING PRACTICE PATTERNS IN ONCOLOGY | |
| Joseph Bailes, MD | ||
| 3:15 | Coffee Time | |
| WHAT EVERY ONCOLOGIST MUST KNOW ABOUT ONCOLOGY EHRS | ||
| Chair: Edward M. Ambinder | ||
| 3:30 | OVERVIEW | |
| Edward P. Ambinder, MD | ||
| 3:35 | THE ASCO/NCI DEFINITION OF THE ONCOLOGY EHR | |
| Peter Yu, MD | ||
| 3:45 | PRINCIPLES OF SAFE PRACTICE: USING AN ONCOLOGY EHR FOR CHEMOTHERAPY ORDERING, PREPARATION & ADMINISTRATION | |
| Larry Shulman, MD | ||
| 3:55 | THE NCI’S caBIG AND THE ONCOLOGIST | |
| To Be Announced | ||
| 4:05 | CHOOSING THE RIGHT EHR FOR YOUR PRACTICE | |
| Carolyn Hartley | ||
| 4:15 | Discussion | |
| 4:25 | LATE BREAKING DEVELOPMENTS | |
| 7-9pm | Dinner and Presentation | |
| AML IN THE OLDER PATIENT | ||
| Harry P. Erba, MD | ||
| SATURDAY, NOVEMBER 14 | ||
| New Perspectives in Oncology Practice | ||
| 8:00 | Expanding role of targeted therapies in leukemia and lymphoma | |
| Karen Stanley, RN, MSN, AOCN, FAAN Immediate Past President, Oncology Nursing Society; Consultant, end-of-life and cancer care issues |
||
| 8:40 | Sexuality and Cancer - Egg Banking | |
| John K. Critser, PhD | ||
| Professor of Veterinary Pathobiology University of Missouri School of Medicine |
||
| 9:00 | Nutritional Management of Chemotherapy Side Effects | |
| Lynn Goldstein, MS, RD, CDN Clinical Dietician, New York Presbyterian Hospital Center for ALS Care, Beth Israel Hospital, NY |
||
| 9:20 | Cost of Cancer Medications in a Slumping Economy | |
| Ricky Newton, CPA Cancer Specialists of Tidewater Virginia |
||
| 9:40 | Sarcomas | |
| Denise Reinke, APRN, BC, AOCN Sarcoma Nurse Practitioner University of Michigan Comprehensive Cancer Center and Administrative Director of SARC (Sarcoma Alliance for Research through Collaboration) Ann Arbor, MI |
||
| 10:20 | Keynote Speaker: David Balch | |
| You Can Handle More Than you Think You Can Caregiver, Consultant, President of The Patient/Partner Project |
||
| 11:00 | Oncologic Emergencies |
|
| Maura Polansky, MS, PA-C MD Anderson Cancer Center Houston, TX |
||
| 11:20 | Multidisciplinary Issues in Head and Neck Cancers | |
| Tara DiFabio, MSN RN CORLN | ||
| Head and Neck Oncology Nurse Practitioner Thomas Jefferson University |
||
| 11:40 | Alternative Coping Mechanisms | |
| Carla Mariano, MSW New York University College of Nursing |
||
| 12:00 pm | Lunch Break | |
| 1:15 | Gastric-Esophageal Cancers | |
| Joyce Griffin-Sobel, PhD, RN, AOCN, APRN-BC, CNE, ANEF Associate Dean Hunter College School of Nursing New York, NY |
||
| 1:35 | Clinical Trials in Oncology Care | |
Shannon Holloway, PA-C, MHS |
||
| 1:55 | Cancer Survival from the Patient’s Perspective | |
Pamela Herman, cancer survivor |
||
| 2:15 | Latest Guidelines and Control Issues for Erythropoetins | |
| Cheryl Gilmartin, PharmD Clinical Assistant Professor Ambulatory Care Pharmacy University of Illinois College of Pharmacy Chicago, IL |
||
| 2:35 | Lung Cancer in Women | |
| Suzanne Walker, RN University of Pennsylvania Health Sciences Center |
||
| 2:55 | Biologics in Cancer Treatment | |
| Gloria Smith, Ph.D., FAAN, FRCN Retired vice president of the W.K. Kellogg Foundation and American Academy of Nursing Living Legend |
||
| 3:15 | The New Technology in Oncology Practice | |
| Edward Ambinder, MD Medical Oncologist Mt. Sinai School of Medicine New York, NY |
||
| 3:35 | Adherence to Oral Medications | |
| Tracy Gosselin, RN Administrative Director Department of Radiation Oncology Duke University Medical Center Durham, NC. |
||
![]()
Conference Management Director: Jaclyn Silverman email: Jaclyn.silverman@mssm.edu | Phone 212 866 2813
A Continuing Education Program of The Chemotherapy Foundation